Regenxbio Inc. (RGNX) Trading Up 6.8%
Shares of Regenxbio Inc. (NASDAQ:RGNX) were up 6.8% on Monday . The company traded as high as $16.47 and last traded at $15.32, with a volume of 243,342 shares. The stock had previously closed at $14.35.
A number of analysts have weighed in on RGNX shares. Piper Jaffray Cos. reaffirmed a “buy” rating and issued a $33.00 price target on shares of Regenxbio in a research report on Tuesday, July 5th. Zacks Investment Research raised Regenxbio from a “hold” rating to a “buy” rating and set a $8.75 price target for the company in a research report on Wednesday, July 6th. Finally, Chardan Capital reissued a “buy” rating on shares of Regenxbio in a research report on Monday, August 22nd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Regenxbio currently has an average rating of “Buy” and a consensus price target of $26.75.
The stock’s market cap is $399.89 million. The stock’s 50-day moving average is $11.17 and its 200 day moving average is $10.85.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/19/regenxbio-inc-rgnx-trading-up-6-8.html
Regenxbio (NASDAQ:RGNX) last released its earnings results on Tuesday, August 9th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.53) by $0.02. Regenxbio had a negative return on equity of 17.89% and a negative net margin of 451.73%. Equities research analysts anticipate that Regenxbio Inc. will post ($2.37) EPS for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in RGNX. Vivo Capital LLC purchased a new position in Regenxbio during the first quarter worth about $10,697,000. BlackRock Advisors LLC boosted its position in Regenxbio by 27,318.5% in the second quarter. BlackRock Advisors LLC now owns 687,657 shares of the company’s stock worth $5,501,000 after buying an additional 685,149 shares during the period. Franklin Resources Inc. boosted its position in Regenxbio by 1,004.9% in the second quarter. Franklin Resources Inc. now owns 700,500 shares of the company’s stock worth $5,604,000 after buying an additional 637,100 shares during the period. BlackRock Fund Advisors boosted its position in Regenxbio by 178.5% in the second quarter. BlackRock Fund Advisors now owns 516,179 shares of the company’s stock worth $4,129,000 after buying an additional 330,862 shares during the period. Finally, Janus Capital Management LLC boosted its position in Regenxbio by 141.2% in the second quarter. Janus Capital Management LLC now owns 527,819 shares of the company’s stock worth $4,223,000 after buying an additional 308,956 shares during the period. Hedge funds and other institutional investors own 68.73% of the company’s stock.
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).
Receive News & Ratings for Regenxbio Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Regenxbio Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.